Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway

被引：126
|
作者：
Sharma, S.
Chopra, K.
Kulkarni, S. K.
Agrewala, J. N.
机构：
[1] Inst Microbial Technol, Immunol Lab, Chandigarh 160036, India
[2] Panjab Univ, Div Pharmacol, Univ Inst Pharmaceut Sci, Chandigarh 160014, India
来源：
CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 2007年 / 147卷 / 01期
关键词：
CD28; CD40; CD80; CTLA-4; curcumin; IL-10; resveratrol;
D O I：
10.1111/j.1365-2249.2006.03257.x
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The role of resveratrol and curcumin is well documented in cancer, inflammation, diabetes and various other diseases. However, their immunosuppressive action on T cells, B cells and macrophages is not well documented. In the present study, we have ascertained the effect of resveratrol and curcumin on T and B cells and macrophages. The most striking findings were that both resveratrol and curcumin suppressed the activity of T and B cells and macrophages, as evidenced by significant inhibition in proliferation, antibody production and lymphokine secretion. Interestingly, curcumin imparted immunosuppression by mainly down-regulating the expression of CD28 and CD80 and up-regulating CTLA-4. Resveratrol also functioned by decreasing the expression of CD28 and CD80, as well as by augmenting the production of interleukin (IL)-10.
引用
收藏
页码：155 / 163
页数：9
相关论文
共 50 条
  • [31] CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics
    vanderMerwe, PA
    Bodian, DL
    Daenke, S
    Linsley, P
    Davis, SJ
    JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (03): : 393 - 403
  • [32] Cattle CTLA-4, CD28 and chicken CD28 bind CD86: MYPPPY is not conserved in cattle CD28
    Parsons, KR
    Young, JR
    Collins, BA
    Howard, CJ
    IMMUNOGENETICS, 1996, 43 (06) : 388 - 391
  • [33] Polymorphisms in CD28, CTLA-4, CD80 and CD86 genes may influence the risk of multiple sclerosis and its age of onset
    Wagner, Marta
    Sobczynski, Maciej
    Karabon, Lidia
    Bilinska, Malgorzata
    Pokryszko-Dragan, Anna
    Pawlak-Adamska, Edyta
    Cyrul, Malgorzata
    Kusnierczyk, Piotr
    Jasek, Monika
    JOURNAL OF NEUROIMMUNOLOGY, 2015, 288 : 79 - 86
  • [34] Involvement of CD70 and CD80 intracytoplasmic domains in the co-stimulatory signal required to provide an antitumor immune response
    Douin-Echinard, V
    Péron, JM
    Lauwers-Cancès, V
    Favre, G
    Couderc, B
    INTERNATIONAL IMMUNOLOGY, 2003, 15 (03) : 359 - 372
  • [35] The localization of CD28 and CTLA-4 in sarcoid lesions
    Yoshimatsu, T
    Tsuda, T
    Matsumoto, T
    Sawabe, T
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A343 - A343
  • [36] Co-Stimulatory and Inhibitory of T Cell: CD28 Family
    Karaselek, Mehmet Ali
    Reisli, Ismail
    ASTIM ALLERJI IMMUNOLOJI, 2016, 14 (02): : 49 - 55
  • [37] Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity
    Crepeau, Rebecca L.
    Ford, Mandy L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (08) : 1001 - 1012
  • [38] Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand:: synergy with the CD28 co-stimulatory pathway
    Melero, I
    Bach, N
    Hellström, KE
    Aruffo, A
    Mittler, RS
    Chen, LP
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1998, 28 (03) : 1116 - 1121
  • [39] CD80/CD28 co-stimulation in human brucellosis
    Skendros, P.
    Boura, P.
    Kamaria, F.
    Raptopoulou-Gigi, M.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2006, 146 (03): : 400 - 408
  • [40] Dynamic regulation of the small GTPase Rap1 by co-stimulatory molecules CD28 and CTLA-4.
    Dillon, TJ
    Stork, PJS
    FASEB JOURNAL, 2004, 18 (08): : C157 - C158
12345